Greco FA, Hainsworth JD. Cancer of unknown primary site. In DeVita VT JrP Hellman S, Rosenberg SA (eds): Cancer: principles and practice of oncology (6th Edn). Philadelphia, PA: Lippincott Williams & Wilkins 2001; pp 2537-2560.
Karsell PR, Sheedy PF, O'Connell MJ. Computed tomography in search of cancer of unknown origin. JAMA 1982; 248: 340-343.
McMillan JH, Levine E, Stephens RH. Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study. Radiology 1982; 143: 143-146.
Blaszyk H, Hartmann A, Bjornsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS 2003; 111: 1089-1094.
Hess KR, Abbruzzese MC, Lenzi R et al. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999; 5: 3403-3410.
Abbruzzese JL, Abbruzzese MC, Hess KR et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12: 1272-1280.
Jordan WE, III, Shildt RA. Adenocarcinoma of unknown primary site. The Brooke Army Medical Center experience. Cancer 1985; 55: 857-860.
Califano J, Westra WH, Koch W et al. Unknown primary head and neck squamous cell carcinoma: Molecular identification of the site of origin. J Natl Cancer Inst 1999; 91: 599-604.
Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 2004; 100: 1776-1785.
van de Wouw AJ, Jansen RL, Speel EJ et al. The unknown biology of the unknown primary tumour: A literature review. Ann Oncol 2003; 14: 191-196.
Stewart JF, Tattersall MH, Woods RL et al. Unknown primary adenocarcinoma: Incidence of overinvestigation and natural history. Br Med J 1979; 1: 1530-1533.
Abbruzzese JL, Abbruzzese MC, Lenzi R et al. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13: 2094-2103.
Pavlidis N, Briasoulis E, Hainsworth J et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39: 1990-2005.
Nystrom JS, Weiner JM, Heffelfinger-Juttner J et al. Metastatic and histologic presentations in unknown primary cancer. Semin Oncoll 1977; 4: 53-58.
Hainsworth JD, Greco FA. Management of patients with cancer of unknown primary site. Oncology (Williston Park) 2000; 14: 563-574.
Summersgill B, Goker H, Osin P et al. Establishing germ cell origin of undifferentiated tumors by identifying gain of 12p material using comparative genomic hybridization analysis of paraffin-embedded samples. Diagn Mol Pathol 1998; 7: 260-266.
Giordano TJ, Shedden KA, Schwartz DR et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 2001; 159: 1231-1238.
Su AI, Welsh JB, Sapinoso LM et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001; 61: 7388-7393.
Dowell JE. Cancer from an unknown primary site. Am J Med Sci 2003; 326: 35-46.
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol 2005; 16: i75-i76.
Pavlidis N, Kalef-Ezra J, Briassoulis E et al. Evaluation of six tumor markers in patents with carcinoma of unknown primary. Med Pediatr Oncol 1994; 22: 162-167.
Nystrom JS, Weiner JM, Wolf RM et al. Identifying the primary site in metastatic cancer of unknown origin. Inadequacy of roentgenographic procedures. JAMA 1979; 241: 381-383.
Le Chevalier T, Cvitkovic E, Caille P et al. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988; 148: 2035-2039.
Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A et al. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003; 44: 1301-1314.
AAssar OS, Fischbein NJ, Caputo GR et al. Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999; 210: 177-181.
Lassen U, Daugaard G, Eigtved A et al. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999; 35: 1076-1082,
Kole AC, Nieweg OE, Pruim J et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82: 1160-1166.
Bohuslavizki KH, Klutmann S, Kroger S et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000; 41: 816-822.
Grau C, Johansen LV, Jakobsen J et al. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 2000; 55: 121-129.
Jungehulsing M, Scheidhauer K, Damm M et al. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000; 123: 294-301.
Nieder C, Gregoire V, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma: Cut down a tree to get an apple? Int J Radiat Oncol Biol Phys 2001; 50: 727-733.
Rades D, Kuhnel G, Wildfang I et al. Localised disease in cancer of unknown primary (CUP): The value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001; 12: 1605-1609,
Greven KM, Keyes JW, Jr., Williams DW III et al. Occult primary tumors of the head and neck: Lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D- glucose. Cancer 1999; 86: 114-118,
Lonneux M, Reffad A. Metastases from Unknown Primary Tumor. PET-FDG as Initial Diagnostic Procedure? Clin Positron Imaging 2000; 3: 137-141.
Alberini JL, Belhocine T, Hustinx R et al. Whole-body positron emission tomography using fluorodeoxyglucose in patents with metastases of unknown primary tumours (CUP syndrome). Nucl Med Commun 2003; 24: 1081-1086.
Standards, Options et Recommandations pour la prise en charge des patients atteints de carcinomes de site primitif inconnu: http://www.fnclcc.fr/ Recommandations pour la pratique clinique/accès aux RPC SOR/Cancer de l'adulte/divers/carcinome de site inconnu/Stratégie diagnostique (online acces 15 february 2006)
Greco FA, Hainsworth JD: Tumors of unknown origin. CA Cancer J Clin 1992; 42: 96-115.
Shildt RA, Kennedy PS, Chen TT et al. Management of patients with metastatic adenocarcinoma of unknown origin: A Southwest Oncology Group study. Cancer Treat Rep 1983; 67: 77-79.
Baron PL, Moore MP, Kinne DW et al. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg 1990; 125: 210-214.
Orel SG, Welnstein SP, Schnall MD et al. Breast MR imaging in patents with axillary node metastases and unknown primary malignancy. Radiology 1999; 212: 543-549.
Kirsten F, Chi CH, Leary JA et al. Metastatic adeno or undifferentiated carcinoma from an unknown primary site - natural history and guidelines for identification of treatable subsets. Q J Med 1987; 62: 143-161.
Tell DT, Khoury JM, Taylor HG et al. Atypical metastasis from prostate cancer. Clinical utility of the immunoperoxidase technique for prostate-specific antigen. JAMA 1985; 253: 3574-3575.
Gentile PS, Carloss HW, Huang TY et al. Disseminated prostatic carcinoma simulating primary lung cancer. Indications for immunodiagnostic studies. Cancer 1988; 62: 711-715.
Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: Recognition of a treatable syndrome. Ann Intern Med 1986; 104: 547-553.
